Vascular complications of scleroderma

Autoimmunity Reviews - Tập 6 - Trang 520-523 - 2007
Serena Guiducci1, Roberto Giacomelli2, Marco Matucci Cerinic1
1Division of Medicine I and Rheumatology, Department of Medicine and Surgery, AOUC, University of Florence, Florence, Italy
2Internal Medicine, University of L'Aquila, School of Medicine, Italy

Tài liệu tham khảo

Kahaleh, 2004, Vascular involvement in systemic sclerosis, Clin Exp Rheumatol, 22, S19 Matuc-Cicerinic, 1997, New approaches to Raynaud's phenomenon, Curr Opin Rheumatol, 544, 9 Cutolo, 2003, Raynaud's phenomenon and the role of capillaroscopy, Arthritis Rheum, 48, 3023, 10.1002/art.11310 Maricq, 1981, Widefield capillary microscopy: technique and rating scale for abnormalities seen in scleroderma and related disorders, Arthritis Rheum, 24, 1159, 10.1002/art.1780240907 Kabasakal, 1996, Quantitative nailfold capillaroscopy findings in a population with connective tissue disease and in normal healthy controls, Ann Rheum Dis, 55, 507, 10.1136/ard.55.8.507 Maricq, 1980, Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders, Arthritis Rheum, 23, 183, 10.1002/art.1780230208 Andrade, 1990, Panoramic nailfold capillaroscopy: a new reading method and normal range, Semin Arthritis Rheum, 20, 21, 10.1016/0049-0172(90)90091-S LeRoy, 1996, Systemic sclerosis. A vascular perspective, Rheum Dis Clin North Am, 22, 675, 10.1016/S0889-857X(05)70295-7 Maricq, 1983, Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease, Clin Exp Rheumatol, 1, 195 Steen, 1990, Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin-converting enzyme (ACE) inhibitors, Ann Intern Med, 113, 352, 10.7326/0003-4819-113-5-352 Coghlan, 2001, The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology, Curr Opin Rheumatol, 13, 495, 10.1097/00002281-200111000-00008 Steen, 2005, Advancements in diagnosis of pulmonary arterial hypertension in scleroderma, Arthritis Rheum, 52, 3698, 10.1002/art.21613 Ramirez, 2004, Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management, Treat Respir Med, 3, 339, 10.2165/00151829-200403060-00002 Hebbar, 2000, Increased concentration of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis, Arthritis Rheum, 43, 889, 10.1002/1529-0131(200004)43:4<889::AID-ANR21>3.0.CO;2-5 Hachulla, 2005, Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study, Arthritis Rheum, 52, 3792, 10.1002/art.21433 Robertson, 2005, Pulmonary arterial hypertension in systemic sclerosis: diagnostic pathway and therapeutic approach, Ann Rheum Dis, 64, 804, 10.1136/ard.2004.026427 Galie, 2004, Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension, J Am Coll Cardiol, 43, 81, 10.1016/j.jacc.2004.02.038 Badesch, 2000, Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial, Ann Intern Med, 132, 425, 10.7326/0003-4819-132-6-200003210-00002 Channick, 2001, New and experimental therapies for pulmonary hypertension, Clin Chest Med, 22, 539, 10.1016/S0272-5231(05)70290-2 White, 2000, Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis, Ann Intern Med, 132, 947, 10.7326/0003-4819-132-12-200006200-00004 Giacomelli, 2002, Cyclophosphamide pulse regimen for the treatment of alveolitis in systemic sclerosis, J Rheumatol, 29, 731 Airo, 2004, Intravenous cyclophosphamide therapy for systemic sclerosis. A single center experience and a review of the literature with pooled analysis of lung function tests results, Clin Exp Rheumatol, 22, 573 Cossio, 2002, Life-threatening complications of systemic sclerosis, Crit Care Clin, 18, 819, 10.1016/S0749-0704(02)00023-4 Zandman-Goddard, 2005, New therapeutic strategies for systemic sclerosis—a critical analysis of the literature, Clin Dev Immunol, 12, 165, 10.1080/17402520500233437 Ramirez, 2004, Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management, Treat Respir Med, 3, 339, 10.2165/00151829-200403060-00002